- Benzinga•last month
Karyopharm Therapeutics Inc. (NASDAQ: KPTI ) revealed the dosing of the first patient in a first stage clinical study evaluating KPT-9274, an oral, first-in-class, dual-acting p21-activated kinase 4 (PAK4) ...
- Capital Cube•last monthKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : June 13, 2016
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Karyopharm Therapeutics, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBearishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving […] (Read more...) The post Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : June 13, 2016 appeared first on CapitalCube.
Karyopharm Therapeutics, Inc.NasdaqGS
Pre-Market: 7.500.14 (1.90%) as of 8:25 AM EDT
|Bid||7.40 x 1000|
|Ask||7.50 x 100|
|52wk Range||4.83 - 22.61|
|Day's Range||7.08 - 7.38|
|Avg Vol (3m)||187,773|
As of 4:00 PM EDT. Market closed.